All Stories

Biohaven's biopolar candidate fails to improve mania in pivotal trial

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.

Mar 4, 2025 - 11:53
 0
Biohaven's biopolar candidate fails to improve mania in pivotal trial
Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial.
Read More

Tags:

Previous Article

Toyota and Lexus appoint Aston Barclay as remarketing partner

Next Article

Researchers use baijiu to power batteries

Related Posts

ElevateBio gene therapy lowers levels of toxic protein in mice with Huntington’s disease

ElevateBio gene therapy lowers levels of toxic protein ...

Feb 28, 2025  0

As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought

As BioMarin searches for 'clever science,' its R&D chie...

Feb 21, 2025  0

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in ...

Feb 12, 2025  0